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Given current constraints on universal treatment campaigns, recent advances in public health prevention ini-
tiatives have revitalized efforts to stem the tide of HIV transmission. Yet, despite a growing imperative for
prevention—supported by the promise of behavioral, structural and biomedical approaches to lower the inci-
dence of HIV—human rights frameworks remain limited in addressing collective prevention policy through
global health governance. Assessing the evolution of rights-based approaches to global HIV/AIDS policy, this
review finds that human rights have shifted from collective public health to individual treatment access. While
the advent of the HIV/AIDS pandemic gave meaning to rights in framing global health policy, the application of
rights in treatment access litigation came at the expense of public health prevention efforts. Where the human
rights framework remains limited to individual rights enforced against a state duty bearer, such rights have faced
constrained application in framing population-level policy to realize the public good of HIV prevention.
Concluding that human rights frameworks must be developed to reflect the complementarity of individual
treatment and collective prevention, this article conceptualizes collective rights to public health, structuring
collective combination prevention to alleviate limitations on individual rights frameworks and frame
rights-based global HIV/AIDS policy to assure research expansion, prevention access and health system
integration.
Introduction
Throughout the evolution of HIV/AIDS policy, institu-
tions of global health governance have looked to human
rights in framing behavioral prevention and medical
treatment initiatives. While leveraging rights-based
policy to protect against coercive prevention measures
and to hold governments accountable for pharmaceut-
ical treatment access, individual human rights remain
limited in guiding global efforts to promote population-
level prevention policy. Given a rising imperative
for HIV prevention—supported by the promise of
behavioral, structural and biomedical approaches to
lower the incidence of HIV and employ treatment as
prevention—it is necessary to reframe the rights-
based mantra of ‘treatment for all’ to include the
collective rights of HIV-negative populations.
Challenging the conventions of the discipline, this
review contests the prevailing rights-based narrative in
global HIV/AIDS policy, guiding a rights-based public
health approach to ‘testing, treatment, and prevention
for all’.
At the intersection of public health ethics and human
rights law, this article analyzes the limited effects of in-
dividual human rights claims in supporting population-
level HIV prevention efforts and conceptualizes a col-
lective rights-based response to address public health
prevention through global health policy. Bridging
theory and policy, this interdisciplinary analysis
provides a framework for research and practice across
public health ethics and global health policy,
advancing collective human rights frameworks to realize
population-level HIV prevention initiatives. This article
begins by reviewing the evolution of global health policy
efforts to address the HIV/AIDS pandemic, chronicling
a global response that originated from an emphasis on
individual behavioral prevention, shifted to focus on
individual access to treatment and has recently sought
to combine individual access to treatment with
population-level prevention. From this public health
background, the authors examine the role of human
rights in the HIV/AIDS response—with attention paid
to the relative emphasis on treatment and prevention—
employing archival research within the United Nations
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(UN) and World Health Organization (WHO) and legal
analysis of global health governance to investigate three
critical stages in the evolution of human rights law in
global HIV/AIDS policy, (i) the birth of the health and
human rights movement, (ii) the creation of interna-
tional legal standards and (iii) the rise of national liti-
gation to assure treatment access. The authors find that
while the development of human rights originated from
a normative focus on underlying determinants of HIV
transmission, these efforts have been reframed through
a litigation-driven effort to realize individual access to
treatment. Where the human rights framework remains
normatively limited to those individual rights enforced
against a state duty bearer, such rights have faced
constrained application in framing population-level
prevention policy. With prevention necessitating
collective rights, rights reflective of the public good of
combination prevention, this analysis examines the
effect of collective rights norms for the public’s health,
concluding that such rights would support global health
policy efforts to slow the spread of HIV through com-
mitments for expanded research, access to prevention
technologies and further integration of HIV prevention,
treatment and care in health systems.
The Prevention Imperative
This section traces the evolution of HIV/AIDS policy in
global health governance, encompassing the institutions
that exercise predominant authority over global deter-
minants of health (Szlezák et al., 2010). In examining
this governance, the authors demonstrate how global
HIV/AIDS policy has transitioned from a narrow
focus on individual behavioral prevention against trans-
mission, to an advocacy focus on individual access to
biomedical treatment, and now, recognizing the limits
of this individual treatment agenda, to an expanded
focus on a combination of behavioral, structural and
biomedical prevention at the population level. This pre-
vention imperative calls into question the adequacy of
the individual human rights paradigm to realize the
highest attainable standard of health.
Building from the first reported cases of HIV, preven-
tion held primacy in early efforts to develop global HIV/
AIDS policy. With no medical response available in the
period before clinical advances in antiretroviral therapy
(ART), early responses to the growing pandemic were
confined to behavioral prevention in the belief that test-
ing, education and counseling—combined with initia-
tives to combat discrimination and provide condoms
and clean needles—would drive self-interested
behavioral change (Bertozzi et al., 2009). Although in-
dividual prevention initiatives predominated from the
mid-1980s to early 1990s, resources for prevention
faded as the public wearied, combination ARTs emerged
and HIV was rebranded a chronic, manageable disease
(Merson et al., 2008). As a result, global HIV policy
shifted from prevention to treatment, driven by advo-
cacy to respond to the dying individual regardless of the
broader public health impact (Benatar et al., 2009).
Beginning with the 1987 approval of zidovudine
(AZT), scientific advancements gave lifesaving hope
for universal HIV treatment; however, this hope was
tempered by its restricted treatment efficacy and pro-
hibitive cost, limitations extended through the 1996
introduction of combination therapy or HAART
(highly active antiretroviral therapy) as the standard of
care for people living with HIV. With the costs of treat-
ment rendering therapies financially inaccessible for
90% of the HIV-positive world (WHO Commission
on Macroeconomics and Health, 2001), HIV remained
a largely fatal diagnosis as infection rates climbed in
developing countries, with Sub-Saharan Africa bearing
the largest share of the global burden (UNAIDS, 2010a).
As the costs of treatment fell and antiretroviral op-
tions expanded, new institutions of global health gov-
ernance emerged to ensure access to treatment and
preservation of life – evolving through the 1997
launch of the Joint United Nations Programme on
HIV/AIDS (UNAIDS); the 2000 adoption of the
Millennium Development Goals (MDGs) and various
declarations on HIV treatment; the 2001 UN General
Assembly Special Session on HIV/AIDS, creating the
Global Fund to Fight AIDS, Tuberculosis, and
Malaria; the 2003 support for the President’s
Emergency Plan for AIDS Relief (PEPFAR) in the
United States and the 2003 start of the 3 by 5 Initiative
through UNAIDS and WHO. Moved by the scale of the
pandemic, developed nations came together in 2005 to
endorse a foreign assistance commitment to attain uni-
versal access to HIV prevention, treatment, care and
support by the year 2010, a target subsequently endorsed
by the UN General Assembly (UK Department for
International Development and the G8 Presidency,
2005). Yet, while this goal of universal access has mobi-
lized unprecedented resources for global health, such
targets for access are increasingly out of reach, and, in
the current economic climate, there are growing con-
cerns that cutbacks in support may lead to a reversal of
treatment gains (Moszynski, 2010; UNAIDS, 2011).
In the face of expanding global efforts to assure treat-
ment, HIV prevalence has continued to grow in the last
15 years, with new HIV infections outpacing ART
264  MEIER ET AL.
initiation and straining already over-burdened treat-
ment distribution programs; for every two people initi-
ating treatment, an estimated five new HIV infections
occur (UN General Assembly, 2010). With an estimated
2.5 million people newly infected with HIV in 2011,
bringing the total number of people living with HIV/
AIDS to 34.2 million (UNAIDS, 2012), recent declines
in HIV incidence have not been widely shared, with
increasing infection rates among high-risk and margin-
alized populations, including commercial sex workers,
men who have sex with men and injection drug users
(Beyrer et al., 2012). Although more than 8 million
people were receiving HIV treatment in low- and
middle-income countries by the end of 2010 (rising
from 6.6 million in 2010 and 5.255 million in 2009),
only an estimated 54% of those in need currently have
access, leaving at least 6.8 million who require treatment
but are not receiving it (UNAIDS, 2012). Given that
‘medical and ethical considerations endow each pa-
tient currently on treatment with a life-long “entitle-
ment” to receive at least his or her current treatment
regimen’, many now consider HIV treatment efforts
‘unsustainable’ (Bongaarts and Over, 2010: 1359).
With current standards focusing on longer treatment
regimens, guaranteeing HAART and regular monitor-
ing to ensure the continued efficacy of treatment, this
standard of care (even with a steady reduction in drug
costs) is often not available for those in resource-limited
settings.
As global HIV/AIDS funding has declined, in parallel
with decreases in other forms of development assistance,
increases in cumulative lifetime HIV treatment costs
have driven a widening gap between rising investment
targets and shrinking financial commitments for HIV
prevention, treatment and care (UNAIDS, 2009; UN
General Assembly, 2010). Following a meteoric rise,
HIV-specific funding has stagnated at 2008 levels, falling
far short of estimates of US$22–24 billion in annual
contributions necessary to achieve universal access to
HIV prevention, treatment, care and support by 2015
(Kates et al., 2012). These decreases in economic assist-
ance are jeopardizing the global community’s ability to
treat every HIV-positive person in the world and to
meet commitments for a lifetime of treatment. As add-
itional people begin first-line treatment—and are forced
by drug resistance to progress to more expensive
second- and third-line therapies—the growing costs of
therapy, care and support will put treatment out of
reach for an increasing share of the HIV-positive
world (Boyd, 2010). Given current budgetary con-
straints, donors may soon reach an untenable retrogres-
sion at the intersection of global health and human
rights, where they could be pressed to take away life-
saving treatment from those already on it. Faced with
HIV incidence rising faster than treatment can begin,
this inability to ‘treat our way out’ of the HIV pandemic
has forced a return to prevention initiatives.
With an intensifying imperative for a shift in global
health governance for HIV/AIDS, a number of initia-
tives have been developed in the last decade to investi-
gate the promise of HIV prevention – that is, to reduce
individual HIV transmission and societal HIV incidence
(Auerbach et al., 2011; Padian et al., 2011). Operating at
both the individual and population level, prevention
engages with policy—as described below and delineated
in Table 1—through a combination of behavioral, struc-
tural and biomedical approaches, including:
 Behavioral approaches, involving an ‘attempt to mo-
tivate behavioral change within individuals and
social units by use of a range of educational, motiv-
ational, peer-group, skills-building approaches and
community normative approaches’ (Coates et al.,
2008: 670), with encouraging developments in
understanding the roles that multiple concurrent
sexual partnerships play in spreading HIV (Mah
and Halperin, 2010);
 Structural approaches, involving an ‘aim to change
the social, economic, political or environmental fac-
tors that determine HIV risk and vulnerability in
specified contexts’ (Gupta et al., 2008: 766), with at-
tention to law reforms and cash transfers (Baird
et al., 2010) and
 Biomedical approaches, involving individual
‘technological’ interventions that do not rely solely
on behavior change to prevent HIV transmission
(Padian et al., 2008: 586), with research showing
groundbreaking advancement in the development
of vaccines (Rerks-Ngarm et al., 2009), curative ini-
tiatives (Margolis, 2011), pre-exposure prophylaxis
(PrEP) (Karim et al., 2010; Baeten et al., 2012), va-
ginal microbicides (Microbicide Trials Network,
2011), treatment as prevention (Cohen et al., 2011;
HIV Prevention Trials Network, 2011) and voluntary
adult male circumcision (Mills et al., 2008).
These prevention opportunities, particularly when com-
prehensively implemented as ‘combination prevention’,
offer a potentially more cost-effective and sustainable
pre-emptive HIV ‘response’ than routinizing testing
and scaling-up treatment, the current norm in HIV
programming.
Under this newly revitalized prevention agenda,
international organizations and national foreign
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assistance programs have incorporated prevention
under global policies for ‘universal access’, drafting
country-level prevention targets to complement those
for treatment and care (Girard et al., 2010). At the fore-
front of global HIV/AIDS policy, UNAIDS and WHO
strategies have set out to ‘revolutionize’ HIV prevention,
calling for innovation and multisectoral efforts to
scale-up prevention initiatives (UNAIDS, 2010b;
WHO, 2010a). Heralding these initiatives ‘Treatment
2.0’, UNAIDS and WHO have sought this new approach
to integrate prevention with treatment – to streamline
the treatment process to ‘achieve and sustain universal
access’ as well as to ‘maximize the preventive benefits of
antiretroviral therapy’ (WHO and UNAIDS, 2011). In
establishing the preventive benefits of therapy, global
policy attention has turned to the effectiveness of
scaling-up individual HIV treatment as a form of
public health prevention, using this ‘test and treat’
model as a means to reduce HIV infectivity and limit
the onward transmission of HIV (Cohen and Gay, 2010;
Powers et al., 2011). Demonstrating the importance of
this ‘test and treat’ model, recent studies have found
that:
(i) seropositive individuals on ART have viral loads
six times lower than comparable individuals
(Kilby et al., 2008),
(ii) the risk of transmission between serodiscordant
couples is reduced 5-fold if the seropositive part-
ner is on ART (Anglemyr et al., 2011) and
(iii) earlier initiation of ART can reduce HIV transmis-
sion by 96% in heterosexual serodiscordant cou-
ples (National Institute of Allergy and Infectious
Diseases, 2011).
Compounded by the recent biomedical successes of
clinical prevention trials for male circumcision, vaginal
microbicides and oral PrEP, policymakers are examin-
ing the relative prioritization of treatment and preven-
tion in global HIV/AIDS policy (Baeten et al., 2010;
Karim et al., 2010; University of Washington
International Clinical Research Center, 2011). Despite
this prevention agenda, HIV prevention continues to
account for only 22% of all HIV/AIDS spending in
low- and middle-income countries, with prevention
strategies inadequately targeted to local contexts of
HIV transmission (UNAIDS, 2010c). Under circum-
stances in which public health realities have led to a
shift in global health governance, it becomes necessary
to recalibrate human rights to reflect this growing im-
perative for targeted HIV prevention paradigms,
re-conceptualizing human rights norms to consider
public health frameworks for global HIV prevention
policy.
Human Rights to Treatment over
Prevention
Despite the evolution of a health and human rights
movement in response to the HIV pandemic and the
application of human rights in developing early HIV/
AIDS policy, human rights obligations are rarely applied
to frame current global HIV prevention efforts. Where
HIV prevention policy is implemented, such public
health interventions are framed on the basis of eco-
nomic efficiency and political feasibility rather than
under the aegis of human rights (Holmes et al., 2012).
Where human rights fulfillment is considered, the right
to health is applied overwhelmingly to individual




 delay sexual debut
 decrease in number of partners
 increased availability and use of condoms
 harm-reduction strategies, including needle
exchange programs
Structural approaches
 law and policy development
 gender equity
 access to services
 cash transfer programs
 decriminalizing determinants of infection








 treatment as prevention
MSM, men who have sex with men; PEP, post-exposure
prophylaxis; STIs, sexually transmitted infections; PMTCT,
prevention of mother-to-child transmission.
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treatment (Gruskin et al., 2007b). This section describes
how rights-based global health governance developed
normatively to create collective obligations for preven-
tion but came to be implemented programmatically
through an individual right to treatment.
Jonathan Mann and the Birth of the Health
and Human Rights Movement
Reversing a history of neglect for human rights in inter-
national health debates, the advent of the HIV/AIDS
pandemic would operationalize human rights for
public health, as scholars and advocates looked explicitly
to human rights in framing the global health response.
As governments responded reflexively to this emergent
threat through traditional public health policies—
including compulsory testing, named reporting, travel
restrictions and isolation or quarantine—human rights
were seen as a reaction to intrusive public health in-
fringements on individual liberty and a bond for
stigma-induced cohesion among HIV-positive activists
(Curran et al., 1987; Kirby, 1988; Bayer, 1991). In this
period of heightened fear and emerging advocacy,
Jonathan Mann’s tenure at WHO marked a turning
point in the application of individual human rights
to public health policy – viewing discrimination as
counterproductive to public health goals, abandoning
coercive tools of public health and applying human
rights to focus on the individual risk behaviors leading
to HIV transmission (Fee and Parry, 2008). Mann’s
vocal leadership of WHO’s Global Programme on
AIDS, launched in 1987, shaped formative efforts to
create a rights-based framework for global health gov-
ernance (Gruskin et al., 2007b). In the absence of med-
ical treatment or biomedical prevention, global HIV/
AIDS policy developed in opposition to both the histor-
ical biomedical framing of international health rights
and the contemporaneous individualistic framing of
neoliberal health policy (Wolff, 2012). Employing be-
havioral science to craft HIV prevention campaigns,
WHO’s first Global Strategy for the Prevention and
Control of AIDS emphasized rights-based access to in-
formation, education and services as a means to support
health autonomy and personal responsibility among
vulnerable individuals (WHO, 1987), an approach sub-
sequently followed in WHO public health guidelines
and UN human rights reports (Centre for Human
Rights, 1991). Drawn explicitly from this human
rights framework, national risk reduction policies
came to stress the need for interventions to respect
and protect human rights as a means to achieve the
individual behavior change that was thought to be ne-
cessary to reduce HIV transmission (WHO, 1988;
Special Rapporteur of the Sub-Commission on the
Prevention of Discrimination and Protection of
Minorities, 1990; Mann and Tarantola, 1998).
Although such rights-based discourses declined precipi-
tously in global health governance following Mann’s
contentious 1990 exit from WHO, Mann continued to
develop this health and human rights movement in
advocating for change in the global HIV response
(Garrett, 1994).
Looking beyond individual behavior, Mann sought to
advance the continuing promise of human rights in ad-
dressing underlying population-level determinants of
health – viewing rights realization as supportive of ‘a
broader, societal approach to the complex problem of
human wellbeing’ (Mann, 1996: 924–925). With recog-
nition of these underlying determinants of HIV, Mann
cautioned that the disease would inevitably descend the
social gradient, calling for rights-based consideration of
socioeconomic, racial and gender disparities in abetting
the spread of HIV (Mann, 1992). Through social scien-
tific examination of the collective determinants of vul-
nerability to HIV infection—challenging the paradigm
of complete individual control over health behaviors, a
central premise of the individual rights framework—the
health and human rights movement could shift from
its early focus on the conflicts between public health
goals and individual human rights (Scheper-Hughes,
1994; Gruskin et al., 1996). Out of this recognition of
an ‘inextricable linkage’ between public health and
human rights, Mann proposed a tripartite framework
to describe the effects of (i) human rights violations on
health, (ii) public health policies on human rights vio-
lations and (iii) human rights protection on public
health promotion (Mann et al., 1999). Given this
focus on population-level determinants of HIV vulner-
ability, Mann argued that ‘since society is an essential
part of the problem, a societal-level analysis and action
will be required’ (Mann, 1999: 222), calling for a
rights-based agenda that would frame policies for the
distribution of costly medical treatments while main-
taining a commitment to prevention efforts focused
on education, access to health services and a supportive
social environment (Mann, 1997a,b). As advocates
adopted this rights-based agenda as a means to frame
public policy reforms, these discourses would take root
in civil society—driven by transnational networks of
public health and social justice advocates—and, despite
Mann’s untimely death, would take hold of an emerging
rights-based movement for global HIV/AIDS policy
(Behrman, 2004).
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International Legal Standards and Public
Health Prevention
Negotiating conflicting agendas at the intersection of
public health and human rights—torn between individ-
ual medical treatment for the present and collective
disease prevention for the future—global health govern-
ance looked to human rights in developing global HIV/
AIDS policy. Integrating human rights norms in HIV/
AIDS partnerships, agendas and strategies, human
rights would play an influential role in framing govern-
mental, intergovernmental and non-governmental re-
sponses to the pandemic, including:
 Governmental—the 1994 International Conference
on Population and Development (ICPD) gave pro-
grammatic direction to rights-based HIV policy,
framing national policies to assure dignity of
HIV-positive individuals (Freedman, 1995).
 Intergovernmental—the 1996 creation of UNAIDS,
drawing on the 1994 Paris Declaration on Greater
Involvement of People Living with HIV and AIDS,
extended efforts to focus on the participation of af-
fected communities in rights-based policy develop-
ment and implementation (UNAIDS, 2000).
 Non-governmental—the 1996 launch of the
International AIDS Vaccine Initiative (IAVI) encour-
aged rights-based scientific research through public-
private partnerships for HIV prevention (Fauci,
2009).
Supported by human rights institutions through a series
of AIDS-related resolutions in the UN Commission on
Human Rights (1995), the UN High Commissioner for
Human Rights sought in 1996 to advance International
Guidelines on HIV/AIDS and Human Rights to elabor-
ate the human rights implicated by both vulnerability to
HIV and access to treatment (Office of the UN High
Commissioner for Human Rights and the Joint UN
Programme on HIV/AIDS, 1998).
Reflecting such rights-based developments in HIV
policy, the UN Committee on Economic, Social and
Cultural Rights took up these evolving issues at the
intersection of global health and human rights in 2000
in drafting its 14th General Comment on economic,
social and cultural rights. Charged with drafting official
interpretations of the International Covenant on
Economic, Social and Cultural Rights (ICESCR), the
Committee interpreted the ICESCR’s human right to
‘disease prevention, treatment and control’ to extend
‘not only to timely and appropriate health care but
also to the underlying determinants of health’ (UN
CESCR, 2000). In implementing this right through the
tools of public health, General Comment 14 included
specific state obligations for ‘the establishment of pre-
vention and education programmes for behaviour-
related health concerns such as sexually transmitted dis-
eases, in particular HIV/AIDS. . .’ (UN CESCR, 2000).
While acknowledging core obligations for the ‘provision
of essential drugs’, the Committee explicitly cautioned
that:
investments should not disproportionately
favour expensive curative health services which
are often accessible only to a small, privileged
fraction of the population, rather than primary
and preventive health care benefiting a far larger
part of the population (UN CESCR, 2000).
Looking past individual behaviors and medical
therapies, the Committee sought to realize a compre-
hensive ‘right to the enjoyment of a variety of facil-
ities, goods, services and conditions’ through state
obligations for underlying population-level determin-
ants of health, assessed on the basis of their avail-
ability, accessibility, acceptability and quality (UN
CESCR, 2000). With this analysis of underlying de-
terminants of health moving beyond individual
rights, recognizing state obligations to assist ‘commu-
nities’, ‘groups’ and ‘populations’, General Comment
14 notes that ‘States parties are bound by both the
collective and individual dimensions of [the right to
health]. Collective rights are critical in the field of
health; modern public health policy relies heavily on
prevention and promotion which are approaches dir-
ected primarily to groups’ (UN CESCR, 2000). In
accordance with the interpretations of other human
rights treaty bodies, the Committee’s application of
human rights to the HIV/AIDS pandemic sought to
de-emphasize individual treatment while recognizing
the influence of public health prevention in address-
ing the interconnected population-level determinants
of HIV transmission (UN Committee on the
Elimination of Discrimination Against Women,
1999; UN Committee on the Rights of the Child,
2003). Extended by the 2001 UN General Assembly
Special Session on AIDS, concretized in the 2002
revision of the International Guidelines on HIV/
AIDS and Human Rights, and elaborated following
the 2002 appointment of the first UN Special
Rapporteur on the right to health, this rights-based
approach to health was seen to be crucial in guiding
and assessing HIV prevention, treatment, care and
support for all (UN General Assembly, 2001; UN
Commission on Human Rights, 2001; Office of the
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UN High Commissioner for Human Rights and the
Joint UN Programme on HIV/AIDS, 2002; Hunt,
2003).
However, as these comprehensive recommendations
for underlying determinants of health required sweep-
ing health systems reforms (expansive changes beyond
the reach of many developing countries), HIV advocacy
shifted from universal population-level prevention
policy to feasible individual medical treatment through
antiretroviral drugs (Berkman, 2001; London, 2002).
Even as experts warned that this access to treatment
agenda came at the expense of public health prevention
programs, human rights litigation advanced popular ef-
forts to realize individual access to treatment, providing
an impactful means to hold states accountable for HIV/
AIDS policy (De Cock et al., 2002; Gostin, 2004).
National Litigation and an Individual Right to
Treatment
The normative evolution of human rights has catalyzed
a burgeoning enforcement movement in global HIV/
AIDS policy, empowering individuals to raise human
rights claims in national courts. With global health poli-
cies emphasizing the importance of the law, legal re-
course and public accountability, litigation has sought
to rectify ‘policy gaps’ and ‘implementation gaps’ in
national HIV/AIDS programs (Tarantola, 2000;
Yamin, 2003). However, with this litigation often
driven by HIV-positive activists, pressing to deliver
medications as an immediate matter of life and death,
this enforcement agenda has focused on treatment to the
exclusion of prevention, neglecting long-term systemic
challenges to address short-term medical imperatives
and consequently distorting the rights-based response
to HIV (Meier and Yamin, 2011).
Driving this litigation movement, the South African
Supreme Court heard an early rights-based challenge for
access to medicines in the seminal 2002 case Minister of
Health v. Treatment Action Campaign (2002). Brought
pursuant to South Africa’s constitutional codification of
the human rights to life and health—providing positive
obligations for the provision of health care—this legal
challenge sought to overturn the national government’s
unwillingness to expand its programs for the distribu-
tion of Nevirapine in reducing the vertical transmission
of HIV from mother to child during childbirth. With
this civil society-driven litigation led by the Treatment
Action Campaign, a South African NGO focused on
treatment for the HIV-positive, these advocates success-
fully held the South African government responsible for
pharmaceutical access (Heywood, 2003).
Despite the origins of this rights-based litigation in
the prevention of mother-to-child transmission, these
rights-based cases would shift toward claims for access
to individual treatment at the expense of policies for
prevention systems (Hogerzeil, 2006; Joint United
Nations Programme on HIV/AIDS, 2006). The
Treatment Action Campaign’s successful claim for
pharmaceutical prevention set a precedent for a wide
range of claims for HIV treatment—developing under
a ‘duty to rescue’ in ethical analysis and expanding
across NGOs through legal advocacy (Pogge, 2007)—
with these claims challenging the monopolistic practices
of the international patent regime and seeking distribu-
tive justice through human rights litigation (Heywood,
2009). Recognizing the resource limitations of develop-
ing states, which were already seeking international as-
sistance to meet domestic demands for treatment, this
treatment access movement soon broadened to impli-
cate international obligations on all manner of powerful
states, organizations and corporations with the ability to
support or impede access to ART in the developing
world (Petchesky, 2003; Forman, 2007). In the wake of
this paradigm shift, reconceptualizing pharmaceutical
knowledge as a global public good, the UN Committee
on Economic, Social and Cultural Rights returned to
these issues in 2006 in General Comment 17,
re-interpreting the right to health to find that states
‘have a duty to prevent unreasonably high costs for
access to essential medicines’ (UN CESCR, 2006).
When the UN Special Rapporteur on the right to
health commented shortly thereafter, he found a
‘human right to medicines’ to form an ‘indispensible
part’ of the right to health, holding that ‘states have to
do all they reasonably can to make sure that existing
medicines are available in sufficient quantities in their
jurisdictions’ (Hunt, 2006).
Although scholars and advocates in the health and
human rights movement have talked passionately
about a human right of access to essential medicines,
this debate on medicines has largely proved the limit of
legal advocacy (Marks, 2009). Such a rights-based focus
on access to health services has reduced the unit of ana-
lysis to the individual, advancing an individual right at
the expense of collective health promotion and disease
prevention programs through public health systems
(Waitzkin, 2001). Although public health has come to
appreciate underlying determinants of health, interna-
tional human rights law has not kept pace with this so-
cietal understanding of health, advancing individual
medical solutions to harms requiring collective societal
change (Chapman, 2002). Operating without regard for
national resource limitations and at the expense of
HUMAN RIGHT TO HIV PREVENTION  269
universal public health measures, human rights litiga-
tion to realize the highest attainable standard of health
for each individual has been criticized for resulting in
programs that: promote selective medical care over pri-
mary health care, distort health policy in ways that take
resources away from other public health threats, under-
mine national health equity through privileging legal
judgments and entrench power rather than empowering
the vulnerable (Easterly, 2009; Ferraz, 2009; Bernier,
2010). Where courts have been faced with challenges
to public health systems—whether in water and sanita-
tion systems, environmental health standards or HIV
prevention programs—individual rights have proven
largely impotent to affect change (Danchin, 2010;
Westra, 2010). Despite theoretical efforts to address
public goods under individual rights, holding that ‘in-
dividual human rights are characteristically exercised,
and can only be enjoyed, through collective action’
(Donnelly, 2003: 25), such theoretical reasoning has
not been translated into rights-based health policy
(Tobin, 2012). With health rights creating at best ‘im-
perfect obligations’ (Sen, 2004), individual human
rights cannot address societal determinants of HIV
transmission. Notwithstanding the rights-based rhetoric
that ‘universal access’ includes prevention as well as
treatment, rights-based claims for access remain pri-
marily focused on treatment, neglecting the rights-based
accountability necessary for programmatic implemen-
tation of global HIV prevention policy (Gruskin and
Tarantola, 2008; Novogrodsky, 2009). While AIDS is
no longer considered exceptional, this human rights
focus on treatment—to the detriment of prevention—
is a public health anomaly that has distorted rights-
based HIV/AIDS policy.
A Human Rights Basis for
Prevention
Where the health and human rights movement has been
constrained in moving beyond access to treatment, this
analysis finds that such limitations stem from an inabil-
ity of human rights to speak with the collective voice
through which HIV prevention must be heard. Enforced
as an individual right against a state duty-bearer, these
inherently limited, atomized rights have proven incom-
plete in creating accountability for public health preven-
tion in global HIV/AIDS policy, impeding efforts to
frame prevention interventions under human rights ob-
ligations (Lieberman, 1999; Chapman, 2002). With
human rights in the global HIV/AIDS response develop-
ing from individual behavioral prevention to individual
medical treatment, it becomes necessary for this un-
steady evolution—as depicted in Figure 1—to encom-
pass collective combination prevention.
Where scholars have contributed ethical arguments in
positing moral commitments to shift global priorities
from treatment to prevention (Brock and Wikler,
2009), there is a need to translate these ethical frame-
works into legal obligations, building a human rights
foundation for scaling-up prevention while maintaining
the political commitments attendant to treatment (Barr
et al., 2011). To bridge the growing disconnect between
individual rights litigation and public health impera-
tives, human rights norms must incorporate collect-
ive rights to public health – rights of societies that
can account for obligations to realize underlying,
population-level determinants of HIV prevention
through national health systems.
Collective rights operate in ways similar to individual
rights; however, rather than seeking the empowerment
of the individual, collective rights act at a societal level to
assure the public goods that cannot be fulfilled through
the absolutist mechanisms of individual entitlements.
Where individual human rights examine ‘a separate iso-
lated individual who, as such and apart from any social
context, is bearer of rights’ (VanderWal, 1990), this
vision of human rights, rooted in autonomy, has
proven incapable of addressing public goods (Ruger,
2006; Parmet, 2009). As seen in the case of indigenous
rights, wherein identity and culture cannot exist at an
individual level, collective rights are seen as necessary to
Figure 1. The evolution of human rights: shifting between individual and collective HIV policy.
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protect group entitlements and minority cultures
(Freeman, 2011). Because these rights inhere in the col-
lective, rather than with each individual member of the
collective, they apply more readily to situations in which
there is a group interest (or solidarity) in the substance
of the right, with the realization of right determined at
the population level (Newman, 2004). Thus, collective
rights frameworks operate at a population level to ad-
dress underlying determinants and assure public goods
that can only be enjoyed in common with similarly
situated individuals.
Although human rights were conceived following
the Second World War as individual rights—with an
individual rights-bearer left to make claims against a
national duty-bearer (and thereby provide external re-
straint against a presumably tyrannical sovereign)—the
rise of developing states and development debates has
forced a re-examination of this individualistic concep-
tion of human rights (Otto, 1995; Donnelly, 2003). With
collective rights originally advanced by the League of
Nations but abandoned by the UN (as the elevation
of group identity was thought to have supported the
ethnic tensions that culminated in the Second World
War), such collective rights were initially avoided in
the development of the post-War human rights system
(Van Dyke, 1982). However, with states maintaining
a collective right to self-determination, this basis for
“solidarity” rights would take root as developing nations
became free from their colonial past, joined the UN and
forced a re-examination of the individualistic concep-
tion of rights (Felice, 1996). Advancing collective rights
anew in response to the economic development limita-
tions of individual human rights frameworks, with de-
veloping states viewing traditional human rights
frameworks as an extension of colonial domination,
environmental health issues were quickly recognized
as a group right (as a healthy environment can only
be enjoyed with others) and were taken up as
part of the movement for global justice through a
New International Economic Order (Cornwall and
Nyamu-Musembi, 2004). Drawing on this political
basis in international relations, scholars and advocates
have since put forward arguments for collective rights
to, inter alia, development, environmental protection,
humanitarian assistance, peace and common heritage
(Marks, 2006).
As applied to public health, wherein public goods
underlie health at a societal level, it has long been recog-
nized in public health ethics that ‘public health and
safety are not simply the aggregate of each private indi-
vidual’s interest in health and safety . . . Public health
and safety are community or group interests’
(Beauchamp, 1985: 29). More than the aggregate of
each individual’s right, population-level prevention is
a societal interest—a whole that is greater than the
sum of its parts—requiring collective rights to hold
duty bearers responsible to populations for the provi-
sion of public goods and necessitating positive action to
provide societal access to behavioral, structural and bio-
medical prevention programs (Meier, 2007). With pre-
vention serving as a public good, as disease prevention
leads to ‘herd immunity’ and impacts entire societies,
collective rights and their corollary implementation
mechanisms become necessary to assure the policies
required to provide for the tools and shared benefits
of public health (Leonard, 2008). Linking ethical
norms with international law, collective rights claims
have shown themselves effective in responding to the
health harms of a globalizing world, shifting the balance
of power in international relations and creating widely
recognized, if not completely realized, entitlements
within the international community (Vandenhole,
2009). Such emerging rights provide a conceptual
framework to develop global HIV prevention policy
for the public’s health.
In framing rights-based tradeoffs in the relative sup-
port of treatment and prevention in global HIV/AIDS
policy, collective rights can prove a means to negotiate
competing ethical frameworks for individual capability,
health equity and public health utility:
 At an individual level, collective rights can address
health capability through prevention interventions,
empowering individuals vulnerable to infection—
particularly high-risk and marginalized populations,
including the young, women, men who have sex with
men, intravenous drug users and commercial sex
workers—to control their own health without relying
on their partners to remove the threat of HIV (Gupta
et al., 2008; Ruger, 2010).
 Moving from individual agency to population-level
agency, collective rights can assure equity, reducing
unjust health disparities across groups by focusing
not simply on the number of individuals on treat-
ment but on the demographic distribution of preven-
tion (and treatment as prevention) across
populations, elevating distributive justice under a
collective unit of analysis (London, 2007).
 At a societal level, collective rights can maximize
public health utility, with prevention serving as a
public good – protecting all of society by: blunting
the chain of HIV infection; reducing burdens of
mortality and morbidity through increased herd im-
munity, decreased drug resistance and improved
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treatment efficacy; and bolstering productivity
among the healthy population in caring for a
smaller infected population (Labonte and
Schrecker, 2007).
Where individual rights are incapable of securing the
public good of disease prevention, incapable of address-
ing the rights of those who are not infected and are
not yet suffering, the collective enjoyment of public
health can be seen as a pre-condition for the individual
human right to health, enabling disease prevention that
can only be achieved at a population level. With public
health prevention addressing collective determinants of
health outside the control of the individual, recognizing
the embeddedness of individuals within their societies,
collective rights can support population-level health
benefits for the common good.
Thus, collective rights to public health can uphold
moral commitments, support ethical norms and pro-
vide legal frameworks for asserting HIV prevention as
a state obligation, with international and non-state ob-
ligations arising where the state is unable or unwilling to
assert its authority to control the spread of HIV (Skogly,
2006). Implemented through the political support for
collective rights among developing states and buttressed
by the normative legitimacy of human rights in global
health governance, such an approach could be codified
in international law and incorporated into political ad-
vocacy for HIV prevention, framing institutional re-
forms, budgetary commitments and accountability
mechanisms in national policy, international organiza-
tions and public–private partnerships. Operating at
both domestic and global levels, such collective rights
would empower states to seek or provide international
assistance and cooperation for HIV prevention in ac-
cordance with their respective abilities, meeting global
public health goals through national health systems and
monitoring national-level epidemiologic indicators
through human rights treaty bodies. As with other
rights-based movements, the interplay between legal de-
velopments and social justice advocacy would create
mutually reinforcing accountability mechanisms in
securing the progressive realization of collective rights
for HIV prevention (Yamin and Gloppen, 2011).
Such a collective lens would best support the
rights-based approach advocated by those who have
proposed early treatment as a means to the public
health benefits of prevention:
Expanded HIV testing and immediate treatment
would offer opportunity for highest quality posi-
tive prevention, a holistic approach that protects
the physical, sexual, and reproductive health of
individuals with HIV, and maximally reduces
onward transmission. Provided coercion is
avoided and confidentiality and dignity main-
tained, individual health and societal safety
should benefit through reduced HIV transmis-
sion, which would enhance human rights overall
(De Cock et al., 2009).
Although concerns have been voiced that such a ‘test
and treat’ model would pose the risk of individual
human rights violations (Rennie and Behets, 2006), par-
ticularly as routinized HIV testing has become the con-
sensus recommendation of global health policymakers
(Jurgens et al., 2009; Amon, 2010), the preponderance
of policy debate has surrounded the prospect of collect-
ive benefits from public health prevention, contemplat-
ing the programmatic feasibility of early treatment to
lower HIV infectivity and thereby reduce the societal
incidence of HIV (Bayer and Edington, 2009;
Zachariah et al., 2011).
Yet, despite the collective advantages of the ‘test and
treat’ approach, this model leaves out the rights of those
who are not HIV-positive, denying them the capability
to prevent their own infection and thus stem the tide of
the HIV pandemic. If collective rights are to frame a
means to testing, treatment and prevention for all,
global health governance must assure that societies can
come together to produce the public good of prevention
and reduce the incidence of HIV toward zero – normal-
izing ‘opt-out’ HIV testing, reducing stigma and
increasing health system utilization through both treat-
ment (for those who are positive) and prevention (for
those who are negative).
In operationalizing collective rights to public health
for the progressive reduction of HIV transmission, the
most obvious approach would be to develop a vaccine
and distribute it to all those who are HIV-negative.
Such a vaccine would promote equitable societal-level
protection against disease while placing few continuing
demands on national health systems (Andre et al.,
2008). Similar to the eradication of smallpox, a universal
vaccination campaign, supporting the public good of
disease eradication, would be uniquely conducive to a
collective rights-based approach to prevention.
However, in a world without the immediate prospect
of a vaccine (Johnston and Fauci, 2008), the most real-
istic operationalization of collective rights would be—as
diagrammed in Figure 2—the expansion of HIV testing
as a universal gateway to the holistic combination of
individual treatment and collective combination
prevention.
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Implemented comprehensively, viewing treatment as
both beneficial to the individual and preventative for the
collective, such an approach would be the rights-based
equivalent of vaccination – with each prevention inter-
vention only partially effective but together serving as a
more perfect societal barrier against a rise in HIV inci-
dence (Hankins and de Zalduondo, 2010). Providing
rights-based frameworks by which combination preven-
tion interventions are appropriate to the epidemiology,
social context and resources of the nation (Auerbach
et al., 2011), collective rights can facilitate accountabil-
ity to assure that prevention interventions are available,
accessible, acceptable and of sufficient quality. To assure
such country-specific scale-up of HIV testing, treatment
and prevention, the implementation of collective rights
through global prevention policy will become crucially
important as research advances, technologies are dis-
tributed and national health systems expand for HIV
prevention.
A Rights-Based Approach to
Global Prevention Policy
With HIV prevention both a public health and a
human rights imperative, human rights law must
frame global health governance to integrate preven-
tion policy as central to the universal access agenda.
A collective rights-based approach can address defi-
ciencies in global health policy for HIV prevention,
facilitating the public’s health through a rights-based
approach to: supporting HIV prevention research,
financing and allocating effective HIV prevention
technologies and incorporating HIV prevention in
primary health care systems.
Expanded Research
Until a cure is found, prevention research will remain
necessary to develop the behavioral, structural and bio-
medical interventions essential to reducing the inci-
dence of HIV. With scientifically-grounded optimism
that such prevention research will soon yield success—
driven by a recent spate of encouraging results from
large-scale clinical trials—an expansion of research
will be critical to assuring international assistance and
cooperation for rights-based approaches to HIV preven-
tion (UNAIDS, 2011). However, HIV prevention trials
have presented novel governance challenges to the evo-
lution of international ethical standards, stymieing the
progression of clinical studies necessary to sustain
research on HIV transmission (Haire et al., 2012). In
carrying out this research, by necessity among vulner-
able high-risk populations in the developing world, it is
necessary that host countries build capacity to approve
and facilitate HIV prevention research with the sup-
port of affected communities (Milford et al., 2006).
To understand the synergistic benefits of treatment
and prevention, establishing a new standard of care for
those taking part in HIV prevention trials, investments
are necessary to develop ‘multiple intervention studies’
on combination HIV prevention – collectively examin-
ing behavioral, structural and biomedical (vaccine and
non-vaccine) prevention at a societal level (Auerbach
et al., 2011).
With prevention research currently on the rise,
collective rights can assure that such research not
look simply at individual clinical trials in isolation,
but extend the beneficial results of previous clinical
research by examining multiple intervention results
at a societal level. While biomedical prevention has
theoretical allure, given recent proof-of-concept re-
sults—for PrEP, microbicides and treatment as
Figure 2. The rights-based equivalency of universal vaccination to universal treatment and collective combination prevention.
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prevention—additional randomized controlled trials
will be necessary to establish societal-level and
context-specific efficacy, feasibility and cost-effective-
ness (Rotheram-Borus et al., 2009). In facilitating
these trials through collective rights, institutional
partnerships between developed and developing
country actors can prove instrumental in developing
the sustainable public health benefits of international
clinical research, overcoming regulatory challenges to
research approval in developing countries and in-
forming the ethical norms of HIV prevention re-
search (Mills et al., 2006; Lagakos and Gable, 2008).
For example, with individual rights frameworks con-
sidering only the risks and benefits to the research
subject, rights-based regulations disadvantage HIV
prevention research where placebo-controlled trials
are necessary to understand combination prevention
at a societal level (Rennie and Sugarman, 2010).
Through the development of ethical standards of
informed consent for those who are HIV-negative,
collective rights would allow for research approval
processes that consider the societal benefits of re-
search (London et al., 2012). Assuring that such re-
search benefits the intended communities, research
populations can employ collective rights to assert
an international obligation to allow active commu-
nity participation in designing prevention research
relevant to the lives of research subjects. With local
consultations among all stakeholders (to understand,
approach and navigate the ethical standards of the
communities in which placebo-controlled studies are
undertaken), the considerations of affected commu-
nities can translate international ethical standards to
reflect local realities (UNAIDS, 2011). To guarantee
such rights-based prevention research, global health
governance must overcome these challenges to HIV
prevention through frameworks that facilitate re-
search review, establish a context-specific standard
of care for affected communities and build research
capacity through country coordination mechanisms
for combination prevention research and community
prevention access.
Prevention Access
To guarantee access to the benefits of this research,
international commitments will be necessary for the dis-
tribution of successful prevention interventions. As with
other global health interventions, research develop-
ments are not always accompanied by ‘clear governance
arrangements to ensure that they are affordable or avail-
able to people who need them’ (Moon, 2009). This is
particularly acute in HIV prevention research, where,
even in the example of the test and treat model, no
rights-based frameworks have been developed to
govern how developed states, international organiza-
tions and industries will commit to providing access
to prospective prevention interventions (Gostin and
Kim, 2011). Where current international commitments
have focused on treatment to the detriment of preven-
tion (Piot et al., 2008; Brock and Wikler, 2009), future
financing mechanisms will be necessary to support the
distribution of HIV prevention (Hecht et al., 2010;
Meyer-Rath and Over, 2012). While a collective rights-
based approach will necessarily involve funding trade-
offs, bearing the immeasurable cost of individual lives
lost for the societal benefit of public health prevention,
such tradeoffs will be essential to assuring the conditions
underlying HIV protection for all.
If developed through the international obligations
inherent in collective rights, global public-private part-
nerships could more efficiently incentivize innovation
and dissemination of HIV prevention. Operating at
the intersection of rights to public health prevention
and rights to ‘enjoy the benefits of scientific progress
and its applications’, these intersectional collective
rights obligations can galvanize international commit-
ments and empower political movements to prioritize
prevention access over intellectual property (Forman,
2008). With individual health-related rights unable to
support entitlements for those who are not unhealthy,
collective rights could better frame the population-level
needs of societies and the international obligations on
developed nations. Implemented programmatically
through advanced market commitments and health
impact funds, such product development partnerships
can overcome uncertain commercial returns that limit
private investment in HIV prevention while employing
non-exclusive royalty contracts to ensure that innov-
ations are accessible in those developing nations that
bear the burdens of intervention development (Koff,
2010). Through such rights-based mechanisms, break-
throughs in behavioral, biomedical and structural pre-
vention can be distributed under the mantle of collective
rights, with these rights framing the rollout of HIV pre-
vention interventions through national health systems.
Health Systems
The implementation of such prevention distribution
will require the revitalization of sustainable national pri-
mary health care systems. Long programmatized in iso-
lation from systems for sexual and reproductive health,
HIV policy implementation is inhibited by an absence of
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systemic infrastructures for the targeting, selection and
delivery of prevention interventions (Bertozzi et al.,
2008). With the weakening of health systems and work-
force resources limiting HIV testing and treatment
(Schneider et al., 2006), health system strengthening
will be necessary to undertake interdependent interven-
tions for universal testing, treatment and prevention –
further integrating these services to sustain funding for
all (Rasschaert et al., 2011). Additionally, given that
combination prevention will require regular testing of
HIV status, sexual education to address HIV risk factors
and administration of biomedical prevention through
health care services—interventions that remain inad-
equate in many developing nations—the distribution
of prevention interventions must account for the
scaling-up of health systems to assure universal access
and the structural reforms to facilitate underlying deter-
minants of HIV prevention (Veenstra and Whiteside,
2009; Global Commission on HIV and the Law, 2012).
As human rights are employed to frame the develop-
ment of health systems, a collective right to HIV pre-
vention would take the AIDS response ‘out of isolation’,
integrating new and existing technologies for HIV treat-
ment and prevention within the context of structural
reforms for the public’s health (Sidibé and Buse,
2009). Despite recent acknowledgement that health
system strengthening and horizontal integration are ne-
cessary for an effective response to AIDS, this health
systems agenda has been unable to ground itself in a
human rights foundation or to raise the international
obligations necessary to prevent and reverse the harms
of health system retrenchment through international
assistance and cooperation (Backman et al., 2008).
With global HIV/AIDS policies and funding resulting
in parallel agendas for HIV and larger issues of sexual
and reproductive health under individual rights frame-
works, a collective right to prevention can support the
integration of vertical HIV prevention efforts in hori-
zontal sexual and reproductive health systems, viewing
health systems as a public good to be realized at a soci-
etal level (Anomaly, 2011). Examining societal public
health indicators rather than individual disease-specific
interventions (Salomon et al., 2007), the ‘implementa-
tion science of HIV prevention’ will be key to this inte-
gration of HIV prevention efforts into broader health
systems (Piot et al., 2008). Despite the complexity of
horizontal health initiatives, governance structures and
funding mechanisms in developing nation contexts,
global health planners and programmers must achieve
optimal programmatic functioning when bringing pro-
grams to scale, particularly in countries with weak and
fragmented health systems and workforces. Similar to
the scale-up of systems for HIV treatment under the
individual right to health (Gruskin et al., 2007a), a col-
lective rights-based approach can frame obligations for
the development of systems to deliver HIV prevention
interventions, focusing on underlying societal deter-
minants of health and assessing population-level epide-
miologic result over medical service provision.
Conclusions
With human rights bearing a central role in the global
HIV/AIDS response, collective rights can reframe the
obligations of global health governance, projecting a
vision of greater justice by addressing the public’s
health through HIV prevention. Where global health
governance has begun to debate the disproportionate
funding targeted at individual HIV treatment—shifting
from a treatment agenda elevated by rights-based advo-
cates to a more pragmatic distribution between treat-
ment and prevention—human rights practitioners
have an opportunity to apply rights-based frameworks
in this evolution of global HIV/AIDS policy. By
engaging collective rights to public health, human
rights can continue to protect populations vulnerable
to HIV infection and structure holistic HIV/AIDS
policy to ensure testing, treatment and prevention
for all.
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